Amgen Says Dazodalibep Regimens Meet Week 48 Primary Endpoint
Amgen said dazodalibep regimens met the primary endpoint at week 48, with significant disease activity reduction.
Amgen said dazodalibep regimens met the primary endpoint at week 48, with significant disease activity reduction.